US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

Parabilis Medicines, Inc. - Common Stock (NQ:PBLS)

22.75 -2.43 (-9.65%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Parabilis Medicines, Inc. - Common Stock

News headline image
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗
Parabilis Medicines is ambitious, but it has Regeneron on its side already. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy? ↗
Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
SpaceX Climbed Nearly 20% in Its First Day of Trading. Here's Where the Stock Price Will Be in 3 Months, According to History. ↗
The Elon Musk-led company has attracted investors' attention in recent days. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering
News headline image
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? ↗
It's important to consider your comfort with risk before diving in. 
Via The Motley Fool
Topics Initial Public Offering